Luxempart has increased its stake in Medios A G and now holds more than 20 per cent of the share capital of the European pharmaceutical services group. The Luxembourg-based investment company acquired a stake in the company in June 2024, with the purchase of 14.9 per cent of the shares from the founder, Manfred Schneider.
Support for Medios’ strategy
Luxempart reaffirms its confidence in the management and in the strategy presented by Medios at its latest investors’ day. “We are delighted to help shape Medios’ future as a trusted partner to the management and staff. The increase in our stake underlines our confidence in the company, its strategy and our long-term commitment to healthcare,” said a member of the Luxempart Group’s Executive Committee, Rudolf Ohnesorge.
Medios focuses on the supply of specialty pharmaceuticals and the preparation of patient-specific therapies. The group works with pharmacies, medical specialists and pharmaceutical companies to facilitate access to treatments, including those for chronic and rare diseases.
Healthcare among investment priorities
Luxempart intends to continue investing in healthcare and supporting the development of companies in the sector. In December 2025, the company announced an agreement to become the majority shareholder in Valeara, which provides outpatient mental healthcare services in Germany. Its portfolio also includes Pflegebutler, an outpatient care provider, and FX Solutions, a specialist in shoulder implants and surgical instruments. Partnerships with specialist fund managers in Europe and North America complement its direct healthcare investments.



